The real status of AMBRI technology will be revealed probably next week when a detailed status announcement should be ready, according to management.
The announcement yesterday was disappointing but until further details become available no one can say how major a set-back.
On my reading of announcement I suspect the problems are now most likely with reproducibility of results between blood samples. That is, main error source is due to effects of different blood samples. This is the first time they have taken the technology into the real world and, as usual for each new step, problems arise.
I expect the old major issues with stability and sensitivity have been resolved by the new cartridge design and work to date.
Reproducibility will be mainly a function of antibodies used and the selectivity to the target antigen and as indicated by the company, solvable.
If I am wrong then time to worry!
ABI Price at posting:
0.0¢ Sentiment: Hold Disclosure: Held
